Anzeige
Meldung des Tages: Das Team hinter UberDoc! Warum Paula Muto, M.D. - und dieses Führungsteam - der eigentliche Katalysator sein könnten

AC Immune News

Aktie
WKN:  A2AR5F ISIN:  CH0329023102 US-Symbol:  ACIU Branche:  Biotechnologie Land:  Schweiz
2,765 €
-0,035 €
-1,25%
16:33:54 Uhr
Depot/Watchlist
Marktkapitalisierung *
265,04 Mio. €
Streubesitz
37,14%
KGV
-4,89
Index-Zuordnung
-

AC Immune News

07.04.26 - GlobeNewswire
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
19.03.26 - GlobeNewswire
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PD TM 2026
13.03.26 - GlobeNewswire
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
05.03.26 - GlobeNewswire
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
24.02.26 - GlobeNewswire
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
11.12.25 - GlobeNewswire
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
11.11.25 - GlobeNewswire
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
04.11.25 - GlobeNewswire
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
28.10.25 - GlobeNewswire
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
24.10.25 - GlobeNewswire
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
25.09.25 - GlobeNewswire
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
Peer-​reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
04.09.25 - GlobeNewswire
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
05.08.25 - GlobeNewswire
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
22.06.25 wallstreetONLINE Redaktion
Blockbuster-Kandidaten: 14 Aktien & 2 ETFs mit Milliardenpotenzial, die wie Bill Gates Alzheimer angehen
Viele forschende Pharmaunternehmen arbeiten intensiv an neuen Alzheimer-​Mitteln, die in den kommenden Jahren auf den Markt kommen könnten. Dies sind die ...
30.04.25 - GlobeNewswire
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
02.04.25 - GlobeNewswire
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-...
25.03.25 - GlobeNewswire
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
13.03.25 - GlobeNewswire
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
04.03.25 - GlobeNewswire
AC Immune to Participate in Upcoming Investor Conferences
AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-​stage biopharmaceutical company ...
10.12.24 - GlobeNewswire
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome ACI-24.060 was generally safe and well tolerated in individuals with Down ...

Newssuche

Videos

newspaper
07.04.26 +5,94%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »